Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001181431-14-002128
Filing Date
2014-01-10
Accepted
2014-01-10 16:40:29
Documents
2
Period of Report
2014-01-08

Document Format Files

Seq Description Document Type Size
1 JAN 2014 GRANTS rrd399593.html 4  
1 JAN 2014 GRANTS rrd399593.xml 4 6551
2 POWER OF ATTORNEY rrd359566_407454.htm EX-24. 3553
  Complete submission text file 0001181431-14-002128.txt   11777
Mailing Address FIRST FLOOR, BLOCK 3, THE OVAL, SHELBOURNE ROAD, BALLSBRIDGE DUBLIN L2 00000
Business Address FIRST FLOOR, BLOCK 3, THE OVAL, SHELBOURNE ROAD, BALLSBRIDGE DUBLIN L2 00000 353 1 6699 020
AMARIN CORP PLC\UK (Issuer) CIK: 0000897448 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O TRANSCEPT PHARMACEUTICALS, INC. 1003 W. CUTTING BLVD., SUITE 110 POINT RICHMOND CA 94804
Business Address
Kennedy Joseph T (Reporting) CIK: 0001408920 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-21392 | Film No.: 14522275